A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Incyte Corporation
Study ID
NCT06380205
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Povorcitinib — DRUG
    Povorcitinib will be administered at protocol defined dose.
  • Levonorgestrel/Ethinyl estradiol — DRUG
    Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.

Study Details

The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.

Key Dates

First listed
Apr 23, 2024
Start date
May 7, 2024
Status verified
Jul 2024
Primary completion
Jun 7, 2024
Completion
Jun 7, 2024

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Povorcitinib + levonorgestrel (LNG)/ethinyl estradiol (EE)
    Povorcitinib and LNG/EE will be administered at the protocol defined doses.

Primary Outcome Measure

Levonorgestrel (LNG) concentration in plasma [ Time Frame: Up to Day 21 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion Clinical Research UnitTempeArizona85283-

Find similar trials in Tempe, AZ

By research site
Celerion Clinical Research Unit· Tempe, AZ

Related Studies